Liaoning Chengda Biotechnology Co. Ltd. Class ASSE: 688739

Announcement on Voluntary Disclosure of the Entry of the Human Papillomavirus15-valent Vaccine (Escherichia Coli) into Phase II Clinical Trials

· Issued by Liaoning Chengda Biotechnology Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Entry of the Human Papillomavirus15-valent Vaccine (Escherichia Coli) into Phase II Clinical Trials

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis